Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

Clinical trial NCT07109323 · RECRUITING

Trial details

NCT number: NCT07109323
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions Cytogenetics Ultra High Risk Primary Refractory Early Progression Plasma Cell Leukemia Non Paraosseous Extramedullary Infiltration R2-ISS-IV /MPSS-IV

Start date: 2025-03-03
Primary completion: 2028-03-02
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.